2022 saw the FDA approval of teplizumab to delay the onset of type 1 diabetes. In addition, there has also been evidence to suggest the effectivness of SGLT2 inhibitors in type 1 diabetes. We were delighted to speak with our editorial board member Prof. Chantal Mathieu (University Hospital Gasthuisberg Leuven, Leuven, Belgium) around this year’s research highlights in these topics and what to look out for in 2023.
Questions
- What are the key clinical highlights from 2022 in the field of diabetes? (0:16)
- What are the hot topics and latest research you are looking forward to exploring in 2023? (2:35)
Disclosures: Chantal Mathieu is a consultant for Novo Nordisk, Sanofi, Merck Sharp and Dohme Ltd., Eli Lilly and Company, Novartis, AstraZeneca, Boehringer Ingelheim, Roche, Medtronic, ActoBio Therapeutics, Pfizer, Imcyse, Insulet, Zealand Pharma, Avotres, Mannkind, Sandoz and Vertex and discloses grant/research support from Medtronic, Imcyse, Novo Nordisk, Sanofi and ActoBio Therapeutics.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Shanice Allen.
